It gets harder and harder to criticize a company's valuation when that
company continues to surpass expectations and build its lead on its
rivals. That is the basic story for Illumina (NASDAQ: ILMN ) , as this company continues to distance itself from Thermo Fisher (NYSE: TMO )
and other would-be sequencing competitors and build up its bona fides
in the diagnostics market. With a diagnostics opportunity at least twice
as large as the $2 billion sequencing market (and growing at a
double-digit rate), there seems to be enough growth potential to keep
investors keenly interested in this name.
Continue reading here:
Illumina Inc's Seemingly Endless Victory Lap
No comments:
Post a Comment